Euonymin is a naturally occurring cardiac glycoside classified as a cardenolide, a class of steroid compounds characterized by a five-membered lactone ring attached at the C-17 position of the steroid nucleus. It is structurally related to other well-known cardiac glycosides such as digoxin and ouabain, sharing the core steroid scaffold but differing in the specific sugar moieties and substitution patterns that influence its pharmacological profile. The compound was first isolated from the bark and roots of plants belonging to the genus Euonymus, commonly known as spindle trees or burning bushes, which are distributed across temperate regions of the Northern Hemisphere.
The primary natural sources of euonymin include Euonymus europaeus (European spindle) and Euonymus atropurpureus (American wahoo), among other species within the Celastraceae family. In these plants, the glycoside accumulates predominantly in the bark, roots, and fruits, where it is thought to serve a defensive function against herbivores and pathogens. Extraction typically involves maceration of dried plant material in polar solvents such as methanol or ethanol, followed by chromatographic purification. The yield varies considerably depending on the species, plant part, season of harvest, and environmental conditions, generally representing a minor constituent of the total extract.
Chemically, euonymin consists of a genin (aglycone) portion, euonymogenin, which is a 3β,14-dihydroxy-5β-card-20(22)-enolide, linked to a trisaccharide chain at the C-3 hydroxyl group. The sugar chain typically comprises two glucose units and one rhamnose or digitoxose unit, though variations in glycosylation have been reported among different Euonymus species. The presence of the 14-hydroxy group on the steroid nucleus and the unsaturated lactone ring are key structural features contributing to its biological activity. The molecular formula is commonly cited as C₃₃H₅₂O₁₅ with a molecular weight of approximately 676.8 g/mol.
Pharmacologically, euonymin exhibits positive inotropic activity characteristic of cardiac glycosides, acting through inhibition of the Na⁺/K⁺-ATPase pump in cardiac myocytes. This inhibition leads to increased intracellular sodium concentration, which subsequently reduces calcium extrusion via the Na⁺/Ca²⁺ exchanger, resulting in enhanced sarcoplasmic reticulum calcium loading and increased contractile force. In vitro and animal studies have demonstrated potency comparable to other cardenolides, though with a reportedly narrower therapeutic index. The compound also displays typical glycoside-related toxic effects, including arrhythmias, gastrointestinal disturbance, and neurological symptoms at supratherapeutic doses, limiting its clinical utility.
Historically, preparations of Euonymus bark were used in traditional medicine by Indigenous peoples of North America and by European herbalists for conditions including dropsy (edema), cardiac insufficiency, and as a cathartic. Euonymin was identified as a major active principle during the late 19th and early 20th centuries, a period of intensive investigation into plant-derived cardiac agents. Despite initial interest, it was largely supplanted by digitalis glycosides, which offered more predictable pharmacokinetics, a wider therapeutic window, and reliable commercial supply from cultivated Digitalis species. Research on euonymin declined significantly after the mid-20th century, though it remains a subject of occasional phytochemical and structure-activity relationship studies.
In contemporary science, euonymin is primarily of academic interest as a reference compound in the study of cardenolide biosynthesis, structure-function relationships within the cardiac glycoside class, and the chemotaxonomy of the Celastraceae. It serves as an analytical standard in the quality control of herbal products containing Euonymus species and in the investigation of potential anticancer properties shared by some cardiac glycosides. No regulated pharmaceutical formulation containing purified euonymin is currently approved for medical use in major regulatory jurisdictions, and the compound is not produced commercially at scale. Its presence in ornamental and invasive Euonymus species continues to be noted in toxicology databases due to the risk of accidental ingestion by humans and livestock.
Euonymin is a naturally occurring cardiac glycoside classified as a cardenolide, a class of steroid compounds characterized by a five-membered lactone ring attached at the C-17 position of the steroid nucleus. It is structurally related to other well-known cardiac glycosides such as digoxin and ouabain, sharing the core steroid scaffold but differing in the specific sugar moieties and substitution patterns that influence its pharmacological profile. The compound was first isolated from the bark and roots of plants belonging to the genus Euonymus, commonly known as spindle trees or burning bushes, which are distributed across temperate regions of the Northern Hemisphere. The primary natural sources of euonymin include Euonymus europaeus (European spindle) and Euonymus atropurpureus (American wahoo), among other species within the Celastraceae family. In these plants, the glycoside accumulates predominantly in the bark, roots, and fruits, where it is thought to serve a defensive function against herbivores and pathogens. Extraction typically involves maceration of dried plant material in polar solvents such as methanol or ethanol, followed by chromatographic purification. The yield varies considerably depending on the species, plant part, season of harvest, and environmental conditions, generally representing a minor constituent of the total extract. Chemically, euonymin consists of a genin (aglycone) portion, euonymogenin, which is a 3β,14-dihydroxy-5β-card-20(22)-enolide, linked to a trisaccharide chain at the C-3 hydroxyl group. The sugar chain typically comprises two glucose units and one rhamnose or digitoxose unit, though variations in glycosylation have been reported among different Euonymus species. The presence of the 14-hydroxy group on the steroid nucleus and the unsaturated lactone ring are key structural features contributing to its biological activity. The molecular formula is commonly cited as C₃₃H₅₂O₁₅ with a molecular weight of approximately 676.8 g/mol. Pharmacologically, euonymin exhibits positive inotropic activity characteristic of cardiac glycosides, acting through inhibition of the Na⁺/K⁺-ATPase pump in cardiac myocytes. This inhibition leads to increased intracellular sodium concentration, which subsequently reduces calcium extrusion via the Na⁺/Ca²⁺ exchanger, resulting in enhanced sarcoplasmic reticulum calcium loading and increased contractile force. In vitro and animal studies have demonstrated potency comparable to other cardenolides, though with a reportedly narrower therapeutic index. The compound also displays typical glycoside-related toxic effects, including arrhythmias, gastrointestinal disturbance, and neurological symptoms at supratherapeutic doses, limiting its clinical utility. Historically, preparations of Euonymus bark were used in traditional medicine by Indigenous peoples of North America and by European herbalists for conditions including dropsy (edema), cardiac insufficiency, and as a cathartic. Euonymin was identified as a major active principle during the late 19th and early 20th centuries, a period of intensive investigation into plant-derived cardiac agents. Despite initial interest, it was largely supplanted by digitalis glycosides, which offered more predictable pharmacokinetics, a wider therapeutic window, and reliable commercial supply from cultivated Digitalis species. Research on euonymin declined significantly after the mid-20th century, though it remains a subject of occasional phytochemical and structure-activity relationship studies. In contemporary science, euonymin is primarily of academic interest as a reference compound in the study of cardenolide biosynthesis, structure-function relationships within the cardiac glycoside class, and the chemotaxonomy of the Celastraceae. It serves as an analytical standard in the quality control of herbal products containing Euonymus species and in the investigation of potential anticancer properties shared by some cardiac glycosides. No regulated pharmaceutical formulation containing purified euonymin is currently approved for medical use in major regulatory jurisdictions, and the compound is not produced commercially at scale. Its presence in ornamental and invasive Euonymus species continues to be noted in toxicology databases due to the risk of accidental ingestion by humans and livestock.
Description
0